Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Effects of Eculizumab Treatment on the Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated in Japan

Yasutaka Ueda, MD PhD, Naoshi Obara, MD PhD, Yuji Yonemura, MD PhD, Hideyoshi Noji, MD PhD, Takahisa Matsuda, Hirozumi Akiyama, Takayuki Ikezoe, MD, PhD, Shigeru Chiba, MD PhD, Yoshinobu Kanda, MD PhD, Tatsuya Kawaguchi, MD PhD, Tsutomu Shichishima, MD PhD, Hideki Nakakuma, MD PhD, Shinichiro Okamoto, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD, Haruhiko Ninomiya, MD PhD

Blood (2017) 130 (Supplement 1): 4749.

https://doi.org/10.1182/blood.V130.Suppl_1.4749.4749

Published: 2017

Journal Articles

Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan

Blood (2014) 124 (21): 4870.

https://doi.org/10.1182/blood.V124.21.4870.4870

Published: 2014

Journal Articles

Pretreatment of Low-Dose Decitabine to Leukemia Cells Markedly Enhances the Cytotoxicity of Gemtuzumab Ozogamicin

Miwa Kurimoto, MD, Hiroshi Matsuoka, MD, PhD, Nobuyoshi Hanaoka, MD, PhD, Shima Uneda, MD, PhD, Takashi Sonoki, MD, PhD, Hideki Nakakuma, MD, PhD

Blood (2011) 118 (21): 5000.

https://doi.org/10.1182/blood.V118.21.5000.5000

Published: 2011

Journal Articles

Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3 Via Mcl-1/Noxa Axis.

Kensuke Kojima, MD, PhD, Marina Konopleva, MD, PhD, Twee Tsao, Michael Andreeff, MD, PhD, Hiroshi Ishida, Yukimasa Shiotsu, PhD, Linhua Jin, PhD, Yoko Tabe, MD, PhD, Hideki Nakakuma, MD, PhD

Blood (2009) 114 (22): 2597.

https://doi.org/10.1182/blood.V114.22.2597.2597

Published: 2009

Journal Articles

Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study.

Yuzuru Kanakura, MD, PhD, Kazuma Ohyashiki, MD, PhD, Tsutomu Shichishima, MD, PhD, Shinichiro Okamoto, MD, PhD, Kiyoshi Ando, MD, PhD, Haruhiko Ninomiya, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Shinji Nakao, MD, PhD, Hideki Nakakuma, MD, PhD, Jun-ichi Nishimura, MD, PhD, Taroh Kinoshita, PhD, Camille Bedrosian, MD, Marye Ellen Valentine, MS, Keiya Ozawa, MD, PhD, Mitsuhiro Omine, MD

Blood (2009) 114 (22): 1980.

https://doi.org/10.1182/blood.V114.22.1980.1980

Published: 2009

Journal Articles

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results.

Yuzuru Kanakura, MD, PhD, Kazuma Ohyashiki, MD, Tsutomu Shichishima, MD, PhD, Shinichiro Okamoto, MD, PhD, Kiyoshi Ando, MD, Haruhiko Ninomiya, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Shinji Nakao, MD, Hideki Nakakuma, MD, PhD, Jun-Ichi Nishimura, MD, PhD, Taroh Kinoshita, PhD, Camille Bedrosian, MD, Marye Ellen Valentine, MS, Keiya Ozawa, MD, PhD, Mitsuhiro Omine, MD

Blood (2008) 112 (11): 3438.

https://doi.org/10.1182/blood.V112.11.3438.3438

Published: 2008

Journal Articles

NKG2D-Mediated Marrow Injury in Paroxysmal Nocturnal Hemoglobinuria and Its Related Disorders.

Nobuyoshi Hanaoka, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Kentaro Horikawa, MD, PhD, Shoichi Nagakura, MD, PhD, Sonoko Ishihara, MD, PhD, Yasuchika Tsuzuki, MD, Yuji Yonemura, MD, PhD, Hideki Nakakuma, MD, PhD

Blood (2007) 110 (11): 3674.

https://doi.org/10.1182/blood.V110.11.3674.3674

Published: 2007

Journal Articles

ULBP and MICA/B as Novel Indicators for Both Diagnosis of Immune-Mediated Marrow Injury and Favorable Response to Immunosuppressive Therapy in Bone Marrow Failure Syndromes.

Nobuyoshi Hanaoka, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Kentaro Horikawa, MD, PhD, Shoichi Nagakura, MD, PhD, Yasuchika Tsuzuki, MD, Yuji Yonemura, MD, PhD, Hideki Nakakuma, MD, PhD

Blood (2006) 108 (11): 990.

https://doi.org/10.1182/blood.V108.11.990.990

Published: 2006

Journal Articles

Appearance of Stress-Inducible Membrane Proteins ULBP on Blood Cells of Patients with PNH, Aplastic Anemia, and MDS: Possible Implication of ULBP in Immune-Mediated Marrow Injury.

Nobuyoshi Hanaoka, MD, Kentaro Horikawa, MD, PhD, Yasuchika Tsuzuki, MD, Shoichi Nagakura, MD, PhD, Sonoko Ishihara, MD, PhD, Hiroaki Mitsuya, MD, PhD, Hideki Nakakuma, MD, PhD, Tatsuya Kawaguchi, MD, PhD

Blood (2005) 106 (11): 1041.

https://doi.org/10.1182/blood.V106.11.1041.1041

Published: 2005

Journal Articles

Decrease in Sensitivity of PIG-A -Mutant Cells to Natural Killer Cells Conferred by Missing of Stress-Inducible Membrane Proteins ULBPs.

Nobuyoshi Hanaoka, MD, Tatsuya Kawaguchi, MD, PhD, Kentaro Horikawa, MD, PhD, Shoichi Nagakura, MD, PhD, Sonoko Ishihara, MD, PhD, Hiroaki Mitsuya, MD, PhD, Hideki Nakakuma, MD, PhD

Blood (2004) 104 (11): 2829.

https://doi.org/10.1182/blood.V104.11.2829.2829

Published: 2004

Journal Articles

Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9.

Jun-ichi Nishimura, MD, PhD, Shahid Nimjee, Haixiang Jiang, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Hideki Nakakuma, MD, PhD, Mitsuhiro Omine, MD, Michael M. Frank, MD, Russell E. Ware, MD, PhD, Bruce A. Sullenger, PhD

Blood (2004) 104 (11): 2824.

https://doi.org/10.1182/blood.V104.11.2824.2824

Published: 2004

NARROW

Effects of Eculizumab Treatment on the Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated in Japan

Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan

Pretreatment of Low-Dose Decitabine to Leukemia Cells Markedly Enhances the Cytotoxicity of Gemtuzumab Ozogamicin

Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3 Via Mcl-1/Noxa Axis.

Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study.

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results.

NKG2D-Mediated Marrow Injury in Paroxysmal Nocturnal Hemoglobinuria and Its Related Disorders.

ULBP and MICA/B as Novel Indicators for Both Diagnosis of Immune-Mediated Marrow Injury and Favorable Response to Immunosuppressive Therapy in Bone Marrow Failure Syndromes.

Appearance of Stress-Inducible Membrane Proteins ULBP on Blood Cells of Patients with PNH, Aplastic Anemia, and MDS: Possible Implication of ULBP in Immune-Mediated Marrow Injury.

Decrease in Sensitivity of PIG-A -Mutant Cells to Natural Killer Cells Conferred by Missing of Stress-Inducible Membrane Proteins ULBPs.

Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only